XML 24 R12.htm IDEA: XBRL DOCUMENT v3.25.1
REVENUE (Notes)
 6 Months Ended
Apr. 30, 2025
Revenue from Contract with Customer [Abstract]  
Revenue from Contract with Customer REVENUE
The following table presents the company’s total revenue and segment revenue disaggregated by geographical region:
Three Months Ended April 30,
20252024
Life Sciences and Diagnostics MarketsAgilent CrossLabApplied MarketsTotalLife Sciences and Diagnostics MarketsAgilent CrossLabApplied MarketsTotal
(in millions)
Revenue by Region
Americas$325 $270 $83 $678 $290 $259 $88 $637 
Europe177 194 71 442 176 182 68 426 
Asia Pacific152 249 147 548 138 223 149 510 
Total$654 $713 $301 $1,668 $604 $664 $305 $1,573 
Six Months Ended April 30,
20252024
Life Sciences and Diagnostics MarketsAgilent CrossLabApplied MarketsTotalLife Sciences and Diagnostics MarketsAgilent CrossLabApplied MarketsTotal
(in millions)
Revenue by Region
Americas$637 $531 $179 $1,347 $573 $512 $182 $1,267 
Europe367 382 156 905 360 367 157 884 
Asia Pacific297 496 304 1,097 291 471 318 1,080 
Total$1,301 $1,409 $639 $3,349 $1,224 $1,350 $657 $3,231 
The following table presents the company’s total revenue disaggregated by end markets and by revenue type:
Three Months EndedSix Months Ended
April 30,April 30,
2025202420252024
(in millions)
Revenue by End Markets
Pharmaceutical and Biopharmaceutical$603 $542 $1,188 $1,107 
Diagnostics and Clinical255 239 495 467 
Academic and Government135 139 272 289 
Chemicals and Advanced Materials369 362 748 754 
Food147 139 315 296 
Environmental and Forensics159 152 331 318 
Total$1,668 $1,573 $3,349 $3,231 
Revenue by Type
Instrumentation$550 $548 $1,175 $1,178 
Non-instrumentation and other1,118 1,025 2,174 2,053 
Total$1,668 $1,573 $3,349 $3,231 

Revenue by region is based on the ship to location of the customer. Revenue by end market is determined by the market indicator of the customer and by customer type. Instrumentation revenue includes sales from instruments, remarketed instruments and third-party products. Non-instrumentation revenue includes sales from contract and per incident services, companion diagnostics, contract development and manufacturing, spare parts, consumables, reagents, vacuum pumps, subscriptions, software licenses and associated services.

Contract Balances

Contract Assets

Contract assets (unbilled accounts receivable) primarily relate to the company's right to consideration for work completed but not billed at the reporting date. The unbilled receivables are reclassified to trade receivables when billed to customers. Contract assets are generally classified as current assets and are included in "Accounts receivable, net" in the condensed consolidated balance sheets. The balances of contract assets as of April 30, 2025 and October 31, 2024, were $289 million and $247 million, respectively.

Contract Liabilities

The following table provides information about contract liabilities (deferred revenue) and the changes in the balances during the six months ended April 30, 2025:
Contract
Liabilities
(in millions)
Ending balance as of October 31, 2024$701 
Net revenue deferred in the period432 
Revenue recognized that was included in the contract liability balance at the beginning of the period(347)
Change in deferrals from customer cash advances, net of revenue recognized16 
Currency translation and other adjustments8 
Ending balance as of April 30, 2025$810 

During the six months ended April 30, 2024 revenue recognized that was included in the contract liability balance at October 31, 2023 was $350 million.
Contract liabilities primarily relate to multiple element arrangements for which billing has occurred but transfer of control of all elements to the customer has either partially or not occurred at the balance sheet date. This includes cash received from customers for products and related installation and services in advance of the transfer of control. Contract liabilities are classified as either current in deferred revenue or long-term in other long-term liabilities in the condensed consolidated balance sheets based on the timing of when we expect to complete our performance obligation.

Contract Costs

Incremental costs of obtaining a contract with a customer are recognized as an asset if we expect the benefit of those costs to be longer than one year. We have determined that certain sales incentive programs meet the requirements to be capitalized. The change in total capitalized costs to obtain a contract was immaterial during the three and six months ended April 30, 2025, and was included in other current and long-term assets on the condensed consolidated balance sheet. We have applied the practical expedient to expense costs as incurred for costs to obtain a contract with a customer when the amortization period would have been one year or less. These costs include the company's internal sales force compensation program, as we have determined that annual compensation is commensurate with annual sales activities.

Transaction Price Allocated to the Remaining Performance Obligations

We have applied the practical expedient in ASC 606-10-50-14 and have not disclosed information about transaction price allocated to remaining performance obligations that have original expected durations of one year or less.
The estimated revenue expected to be recognized for remaining performance obligations that have an original term of more than one year, as of April 30, 2025, was $429 million, the majority of which is expected to be recognized over the next 12 months. Remaining performance obligations primarily include extended warranty, customer manufacturing contracts, software maintenance contracts and revenue associated with lease arrangements.